Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 7Genitourinary 3Head & Neck 2Breast 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Lymphocytic, Chronic, B-Cell 4Primary Myelofibrosis 3Multiple Myeloma 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myeloid, Accelerated Phase 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Prolymphocytic 2Leukemia, Mast-Cell 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Hodgkin Disease 2Hematologic Neoplasms 2Congenital Abnormalities 2Carcinoma, Renal Cell 2Breast Neoplasms 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

Cyclophosphamide 4sargramostim 3Psychiatric Rehabilitation 3Paclitaxel 3Flow Cytometry 3trametinib 2pertuzumab 2pembrolizumab 2dabrafenib 2Trastuzumab 2Specimen Handling 2Palliative Care 2Methylprednisolone 2Melphalan 2Magnetic Resonance Spectroscopy 2Immunologic Techniques 2Filgrastim 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2varlilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1tanespimycin 1stenoparib 1sapanisertib 1ruxolitinib 1rucaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Sunitinib × Other hematologic neoplasm × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡